Ann: Mesoblast Newsletter on Advanced and End-Stage Heart Failure, page-40

@AndyL2880 it is just as well you don't write releases  ,  you wrote;

"Now let’s say the message from MSB was “we are doing our best to ensure a timely outcome but are not in a position to assert any control over the progress of this submission, but based on our duscussions with the trial team we are under guidance that they will begin submission consultationsy with the FDA in the first half of 2019”. Something like that conveys a lot information about the state of play."

I think it gets things a bit confused about who is going to do what.